Tn-Miner: Technology for the Discovery of Tumor-specific Glycopeptide Immunotherapy Targets.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Sponsor
- University Ghent
- Enrollment
- 36
- Locations
- 4
- Primary Endpoint
- Discovery of new, tumor-specific, glycopeptide epitopes.
Study Overview
Brief Summary
The goal of this interventional, prospective research on human bodily material is to discover new, cancer-specific molecular structures (i.e. glycopeptides) within surgically removed, estrogen receptor positive breast cancer tumors.
The main goal it aims to achieve is:
To discover tumor-specific targets, that allow the use of very potent immunotherapeutic drugs as treatment for solid tumors, such as estrogen receptor positive breast cancer. These new targets are very specific for cancer cells, meaning that virtually no healthy cells should be attacked by the treatment, resulting in less side effects.
Participants will undergo standard of care treatment, comprising surgical removal of the breast tumor. Part of these tissues will be used for this clinical research.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Minimally 18 years old
- •Diagnosed with estrogen-receptor positive breast cancer
- •This must be a primary tumor
Exclusion Criteria
- •Younger than 18 years old
- •Previous history of other tumors
Outcomes
Primary Outcomes
Discovery of new, tumor-specific, glycopeptide epitopes.
Time Frame: The patients are only involved during their standard of care surgery (one day). The discovered epitopes will not be shared with enrolled patients.
The discovery of new antigens, comprising both glycan and peptide (=glycopeptide), on the outside of the plasma membrane of the breast cancer cells. These antigens should be absent on healthy cells. These new, glycopeptide antigens can be used as target for immunotherapeutics against cancer.
Secondary Outcomes
No secondary outcomes reported